---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-054726"
form_type: "8-K"
ticker: "AKTX"
cik: "0001541157"
company_name: "Akari Therapeutics Plc"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T18:04:05.505707+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Akari Therapeutics reduces workforce by 67% after suspending HSCT-TMA program

## Summary
- Workforce reduction of ~67% implemented May 1, 2024; includes elimination of senior management positions.
- Expected severance and related costs $3.1–3.2M, including ~$1.6M non-cash equity vesting; costs payable through Q4 2024.
- Board member Rachelle Jacques resigned May 7, 2024; board reduced to five members with no disagreement reported.
- Reduction is part of restructuring to cut HSCT-TMA operating costs and support long-term strategic plan.

## SEC filing metadata
- accession: 0000950170-24-054726
- form_type: 8-K
- ticker: AKTX
- cik: 0001541157
- company_name: Akari Therapeutics Plc
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/0000950170-24-054726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/aktx-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-054726
- JSON: https://secwatch.observer/filing/0000950170-24-054726.json
- Plain text: https://secwatch.observer/filing/0000950170-24-054726.txt

## Key facts
- Executive change
  Rachelle Jacques resigned as Director at Akari Therapeutics Plc.
  - Action: resigned
  - Role: Director
  source text: On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the “Board”), effective May 7, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/0000950170-24-054726-index.htm
- Restructurings & Charges
  Akari Therapeutics Plc announced a restructuring with charges of approximately $3.1 million to $3.2 million (approximately 67% of its total workforce).
  - Type: restructuring
  - Charge: approximately $3.1 million to $3.2 million
  - Headcount: approximately 67% of its total workforce
  source text: expects expenses related to the reduction-in-force, consisting primarily of cash severance and termination benefits and related costs, to be in the range of approximately $3.1 million to $3.2 million, which includes approximately $1.6 million of non-cash expenses related to vesting of equity awards. The Company expects these costs to be payable through the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1541157/000095017024054726/0000950170-24-054726-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.